Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 04, 2022

Enasidenib as Maintenance Following Allogeneic HCT for IDH2-Mutated Myeloid Malignancies

Blood Advances


Additional Info

Disclosure statements are available on the authors' profiles:

Blood Advances
Enasidenib as Maintenance following Allogeneic Hematopoietic Cell Transplantation for IDH2-Mutated Myeloid Malignancies
Blood Adv 2022 Sep 23;[EPub Ahead of Print], AT Fathi, HT Kim, RJ Soiffer, MJ Levis, S Li, AS Kim, AS Mims, Z DeFilipp, A El-Jawahri, SL McAfee, AM Brunner, R Narayan, LW Knight, D Kelley, AS Bottoms, LS Perry, JL Wahl, J Brock, E Breton, VT Ho, YB Chen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading